Quarterly ResultMay 5, 2026, 06:41 AM
IDEXX Q1 Revenue $1.14B, +14%; Raises 2026 Revenue & EPS Guidance
AI Summary
IDEXX Laboratories reported strong first-quarter 2026 results, with revenue increasing 14% to $1.14 billion and diluted EPS rising 17% to $3.47. The company achieved double-digit organic revenue growth across its Companion Animal Group, Water, and Livestock, Poultry and Dairy segments, driven by commercial execution and innovation. Reflecting this performance, IDEXX raised its full-year 2026 revenue guidance to $4.675-$4.760 billion and its EPS outlook to $14.45-$14.90. The company also highlighted momentum for its IDEXX Cancer Dx™ platform and the rollout of IDEXX inVue Dx™ with 1,100 placements.
Key Highlights
- Q1 2026 Revenue: $1.14 billion, up 14% reported and 11% organic.
- Q1 2026 Diluted EPS: $3.47, up 17% reported and 15% comparable.
- Q1 2026 Operating Margin: 31.8%, up 100 bps on a comparable basis.
- Q1 2026 CAG Diagnostics recurring revenue: up 14% reported and 11% organic.
- Q1 2026 CAG Diagnostics capital instrument revenues: up 33% reported and 28% organic, with 1,100 inVue Dx placements.
- 2026 Revenue Guidance raised to $4.675-$4.760 billion, up $42 million at midpoint.
- 2026 EPS Outlook raised to $14.45-$14.90, up $0.13 at midpoint.
- 2026 Operating Margin Outlook: 32.1%-32.5%, projecting 50-90 bps expansion.